A suggestion has been made to use oral IgA in patients with sIgAD, since this deficiency is associated with dysbiosis and chronic inflammation, and the present inflammation is inversely correlated with systemic anticommensal IgG response, which acts as “second line of defense” [86,87]. The gene discussed is CD79A; the disease is selective IgA deficiency disease.